Effect of the new antiepileptic drug retigabine in a rodent model of mania

Epilepsy and Behavior

Volumn 12, Issue 1, 2008, Pages 49-53

  Dencker, Ditte ^a   Dias, Rebecca ^a   Pedersen, Mette Lund ^a   Husum, Henriette ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Animal model; Bipolar disorder; KCNQ; Kv7; Lamotrigine; Lithium; Mania; Rat; Retigabine

Indexed keywords

AMPHETAMINE; CHLORDIAZEPOXIDE; CITALOPRAM; LAMOTRIGINE; LITHIUM CHLORIDE; RETIGABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; HYPERACTIVITY; LOCOMOTION; MALE; MANIA; NONHUMAN; RAT; WISTAR RAT;

AMPHETAMINE; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; BIPOLAR DISORDER; CARBAMATES; CHLORDIAZEPOXIDE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; LITHIUM CHLORIDE; MALE; MOTOR ACTIVITY; PHENYLENEDIAMINES; RATS; RATS, WISTAR; TRIAZINES;

EID: 37049038680     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2007.09.023     Document Type: Article

References (33)

1. Cooper E.C., and Jan L.Y. M-channels: neurological diseases, neuromodulation, and drug development. Arch Neurol 60 (2003) 496-500
2. Passmore G.M., Selyanko A.A., Mistry M., et al. KCNQ/M currents in sensory neurons: significance for pain therapy. J Neurosci 23 (2003) 7227-7236
3. Yus-Najera E., Munoz A., Salvador N., et al. Localization of KCNQ5 in the normal and epileptic human temporal neocortex and hippocampal formation. Neuroscience 120 (2003) 353-364
4. Jentsch T.J. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 1 (2000) 20-21
5. Main M.J., Cryan J.E., Dupere J.R., Cox B., Clare J.J., and Burbidge S.A. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 58 (2000) 253-262
6. Tatulian L., Delmas P., Abogudie F.C., and Brown D.A. Activation of expressed KCNQ potassium currents and native neuronal m-type potassium currents by the anticonvulsant drug retigabine. J Neurosci 21 (2001) 5535-5545
7. Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. Science 279:403-6.
8. Blackburn-Munro G., Dalby-Brown W., Mirza N.R., Mikkelsen J.D., and Blackburn-Munro R.E. Retigabine: chemical synthesis to clinical application. CNS Drug Rev 11 (2005) 1-20
9. + channels in bipolar disorder. Pharmacogenomics 7 (2007) 123-132
10. Rush A.J., Keller M.B., Bauer M.S., Dunner D., Frank E., and Klein D.F. Diagnostic and statistical manual of mental disorders-fourth edition (DMS-IV) (2000), American Psychiatric Assoc., Arlington, VA p. 345-428
11. Goodwin G.M. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17 (2003) 149-173
12. Plosker G.L., and Scott L.J. Retigabine: in partial seizures. CNS Drugs 20 (2006) 601-608
13. Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics 2007;4:149-54.
14. Einat H. Establishment of a battery of simple models for facets of bipolar disorder: a practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease. Behav Genet 37 (2007) 244-255
15. Machado-Vieira R., Kapczinski F., and Soares J.C. Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 209-224
16. Aylmer C.G., Steinberg H., and Webster R.A. Hyperactivity induced by dexamphetamine/chlordiazepoxide mixtures in rats and its attenuation by lithium pretreatment: a role for dopamine?. Psychopharmacology (Berlin) 91 (1987) 198-206
17. Rushton R., and Steinberg H. Combined effects of chlordiazepoxide and dexamphetamine on activity of rats in an unfamiliar environment. Nature 211 (1966) 1312-1313
18. Lamberty Y., Margineanu D.G., and Klitgaard H. Effect of the new antiepileptic drug levetiracetam in an animal model of mania. Epilepsy Behav 2 (2001) 454-459
19. Cao B.J., and Peng N.A. Magnesium valproate attenuates hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents. Eur J Pharmacol 237 (1993) 177-181
20. Vale A.L., and Ratcliffe F. Effect of lithium administration on rat brain 5-hydroxyindole levels in a possible animal model for mania. Psychopharmacology (Berlin) 91 (1987) 352-5
21. Arban R., Maraia G., Brackenborough K., et al. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav Brain Res 158 (2005) 123-132
22. Einat H., Manji H.K., and Belmaker R.H. New approaches to modeling bipolar disorder. Psychopharmacol Bull 37 (2003) 47-63
23. Wickenden A.D. Potassium channels as anti-epileptic drug targets. Neuropharmacology 43 (2002) 1055-1060
24. Wuttke T.V., Seebohm G., Bail S., Maljevic S., and Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 67 (2005) 1009-1017
25. Rundfeldt C., and Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine: interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 50 (2000) 1063-1070
26. Kapczinski F., Frey B.N., and Zannatto V. Physiopathology of bipolar disorders: what have changed in the last 10 years?. Rev Bras Psiquiatr 26 Suppl. 3 (2004) 17-21
27. Seiden L.S., Sabol K.E., and Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33 (1993) 639-677
28. Mikkelsen J.D. The KCNQ channel activator retigabine blocks haloperidol-induced c-Fos expression in the striatum of the rat. Neurosci Lett 362 (2004) 240-243
29. Hansen H.H., Ebbesen C., Mathiesen C., et al. The KCNQ opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat. J Pharmacol Exp Ther 318 (2006) 1006-1019
30. Amann B., Sterr A., Vieta E., Stampfer R., Walden J., and Grunze H. An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients. J Clin Psychopharmacol 26 (2006) 534-536
31. Grunze H., von W.J., Greene R.W., and Walden J. Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology 38 (1998) 131-138
32. Olpe H., Kolb C.N., Hausdorf A., and Haas H.L. 4-Aminopyridine and barium chloride attenuate the anti-epileptic effect of carbamazepine in hippocampal slices. Experientia 47 (1991) 254-257
33. Walden J., Altrup U., Reith H., and Speckmann E.J. Effects of valproate on early and late potassium currents of single neurons. Eur Neuropsychopharmacol 3 (1993) 137-141